Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells.

导出 OA

翻译打印收藏纠错

作者： Nayanendu,Saha ^[1] ; Kai,Xu ^[2] ; Zhongyu,Zhu ^[3] ; Dorothea,Robev ^[1] ; Teja,Kalidindi ^[4] ; Yan,Xu ^[2] ; Juha,Himanen ^[1] ; Elisa,de Stanchina ^[5] ; Naga Vara Kishore,Pillarsetty ^[4] ; Dimiter S,Dimitrov ^[6] ; Dimitar B,Nikolov ^[1]

作者单位： Structural Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States. ^[1] Department of Veterinary Bioscience, Ohio State University, Columbus, OH 43210, United States. ^[2] Lentigen, a Miltenyi Biotec Company, Gaithersburg, MD 20878, United States. ^[3] Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States. ^[4] Antitumor Assessment Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States. ^[5] Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15260, United States. ^[6]

关键词 ADAM17 Cancer therapy EGFR signaling Monoclonal antibody

DOI 10.1016/j.tranon.2021.101265

PMID 34768098

发布时间 2022-02-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交